Can Twist Bioscience Drop More?

Core Insights - Twist Bioscience (TWST) stock has experienced a significant decline of 10.1% in one day, raising concerns about potential deeper issues beyond temporary weakness [2] - The company is valued at $1.6 billion with a revenue of $362 million, and its stock is currently trading at $26.87 [2] - Revenue growth over the past year is reported at 22.7%, but the operating margin stands at -39.3% [2] - The stock is trading at a P/E multiple of -18.9 and a P/EBIT multiple of -9.5, indicating moderate operational performance and valuation, leading to it being considered fairly priced [3] Financial Position - The company has a debt-to-equity ratio of 0.05 and a cash-to-assets ratio of 0.39, suggesting a strong liquidity position [2] - TWST stock has historically underperformed compared to the S&P 500 during economic downturns, with a notable decline of 94.5% from its peak of $207.97 on January 20, 2021, to $11.49 on May 2, 2023 [7] - The stock has not yet returned to its pre-crisis high, with the highest price since then being $58.88 on July 23, 2024 [7] Market Performance - The stock dropped 43.9% from a high of $35.15 on March 6, 2020, to $19.71 on March 18, 2020, compared to a 33.9% decline for the S&P 500 [7] - In December 2018, TWST stock declined by 47.6% from a peak of $31.08 to $16.30, while the S&P 500 experienced a peak-to-trough decline of 19.8% [8] - Despite these declines, the stock has shown the ability to fully rebound to its pre-crisis peaks in previous instances [8]